NCT02841995View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

May 12, 2022

Study Completion Date

May 12, 2022

Conditions
Graft vs Host Disease
Interventions
DRUG

Belumosudil (KD025)

Pharmaceutical form: Capsules or Tablets Route of administration: Oral

Trial Locations (7)

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

37232

Vanderbilt University Medical Center, Nashville

45242

Oncology Hematology Care, Cincinnati

55455

University of Minnesota, Minneapolis

78229

Texas Transplant Institute, San Antonio

91010

City of Hope National Medical Center, Duarte

98109

Fred Hutchinson Cancer Center, Seattle

All Listed Sponsors
lead

Kadmon, a Sanofi Company

INDUSTRY

NCT02841995 - A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease | Biotech Hunter | Biotech Hunter